I read with great interest the blog “Avastin W” by John A. Hovanesian, whom I would like to congratulate for touching on a delicate argument that affects the quality of life of individuals affected by macular and retinal diseases.
In many countries, the incidence of blindness due to age-related maculopathy and diabetic retinopathy has been halved thanks to the efficient use of intravitreal anti-VEGF agents. On the other hand, this shift toward newer therapeutic pharmaceutical options has made eye services more costly as compared with the times in which laser was the only offer for